Verve Therapeutics (VERV) Expected to Announce Quarterly Earnings on Wednesday

Verve Therapeutics (NASDAQ:VERV) is projected to release its Q1 2025 earnings data before the market opens on Wednesday, May 14th. Analysts expect Verve Therapeutics to post earnings of ($0.71) per share for the quarter.

Verve Therapeutics (NASDAQ:VERV) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.14. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The business had revenue of $13.08 million for the quarter, compared to the consensus estimate of $3.94 million. On average, analysts expect Verve Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Verve Therapeutics Price Performance

Shares of VERV stock opened at $4.35 on Tuesday. The company has a market cap of $387.77 million, a price-to-earnings ratio of -1.77 and a beta of 1.82. Verve Therapeutics has a 1 year low of $2.86 and a 1 year high of $9.31. The firm has a fifty day moving average price of $4.94 and a 200-day moving average price of $5.91.

Analyst Upgrades and Downgrades

VERV has been the subject of a number of analyst reports. Canaccord Genuity Group upped their price target on Verve Therapeutics from $32.00 to $39.00 and gave the stock a “buy” rating in a research report on Tuesday, April 15th. Royal Bank of Canada cut their price objective on Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating for the company in a research note on Tuesday, March 4th. William Blair restated an “outperform” rating on shares of Verve Therapeutics in a research note on Friday, February 21st. Cantor Fitzgerald upgraded shares of Verve Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Tuesday, April 15th. Finally, Guggenheim increased their price objective on shares of Verve Therapeutics from $18.00 to $24.00 and gave the stock a “buy” rating in a research note on Tuesday, April 15th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $25.75.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.